Small molecule-based therapy for Visceral pain: TWIST1 decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 15/February/2015, 21.27

Mechanistic into tumorigenesis: p-ΔNp63α increases the expression of HOXA11 and decreases the expression of tumor suppressor p53 via down regulation of its target gene, 15/February/20145, 20.14
February 15, 2015
MiRNA-based anticancer therapy: Tumor suppressor MiRNA-218 suppresses the expression L1CAM via down regulation of their target genes, 15/February/20145, 22.04
February 15, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Small molecule-based therapy for Visceral pain: TWIST1 decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 15/February/2015, 21.27, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that TWIST1, by increasing the expression of its target gene, it may decrease visceral pain in patients with Irritable Bowel Syndrome.  Thus, pharmacological formulations encompassing “TWIST1 activators  may be used to treat visceral pain.

Amount: $ 500*

Undisclosed information: How  TWIST1 decreases visceral pain

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.